Evidence and resources to implement pharmacogenetic knowledge for precision medicine

American Journal of Health-System Pharmacy

Volumn 73, Issue 23, 2016, Pages 1977-1985

  Caudle, Kelly E ^a   Gammal, Roseann S ^a,b   Whirl Carrillo, Michelle ^c   Hoffman, James M ^a   Relling, Mary V ^a   Klein, Teri E ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CPIC; Evidence; Guideline; Pharmacoge nomics; Pharmacogenetics; PharmGKB; Precision medicine

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DRUG RESPONSE; EVIDENCE BASED PRACTICE; GENETIC VARIABILITY; GENETIC VARIATION; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION DISSEMINATION; INFORMATION PROCESSING; KNOWLEDGE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); EVIDENCE BASED MEDICINE; GENETIC DATABASE; PROCEDURES; RESOURCE ALLOCATION; TRENDS;

DATABASES, GENETIC; EVIDENCE-BASED MEDICINE; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE; RESOURCE ALLOCATION;

EID: 84995874900     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150977     Document Type: Article

References (53)

1. Relling MV, Evans WE. Pharmacoge-nomics in the clinic. Nature. 2015; 526:343-50.
2. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011; 89:464-7.
3. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther. 2014; 96:655-7.
4. Ratain MJ, Johnson JA. Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014; 96:650-2.
5. Khanal A, Castelino RL, Peterson GM et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J. 2014; 44:77-85.
6. ∗5701 screening for abacavir hypersensitivity in North America. AIDS. 2008; 22:1673-5.
7. Filipski KK, Mechanic LE, Long R et al. Pharmacogenomics in oncology care. Front Genet. 2014; 5:73.
8. Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013; 369:2294-303.
9. Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369:2283-93.
10. Baker WL, Johnson SG. Pharmaco-genetics and oral antithrombotic drugs. Curr Opin Pharmacol. 2016; 27:38-42.
11. Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing - recalibrating expectations. N Engl J Med. 2013; 369:2273-5.
12. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med. 2013; 369:2345-6.
13. Drozda K, Wong S, Patel SR et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2015; 25:73-81.
14. Evans WE, Crews KR, Pui CH. A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther. 2013; 94:224-9.
15. Johnson SG Leading clinical pharmacogenomics implementation: advancing pharmacy practice. Am J Health-Syst Pharm. 2015; 72:1324-8.
16. Saito Y, Stamp LK, Caudle KE et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016; 99:36-7.
17. Leape LL, Berwick DM, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA. 2002; 288:501-7.
18. Shekelle PG, Wachter RM, Pronovost PJ et al. Making health care safer II: an updated critical analysis of the evidence for patient safety practices. Evid Rep Technol Assess (Full Rep). 2013; 211:1-945.
19. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther. 2011; 89:662-73.
20. Swen JJ, Wilting I, de Goede AL et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 2008; 83:781-7.
21. Clinical Pharmacogenetics Implementation Consortium. https://cpicpgx.org/ (accessed 2016 Mar 16).
22. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92:414-7.
23. Caudle KE, Klein TE, Hoffman JM et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014; 15:209-17.
24. Teutsch SM, Bradley LA, Palomaki GE et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med. 2009; 11:3-14.
25. The Pharmacogenomics Knowledgebase. www.pharmgkb.org/ (accessed 2016 Mar 16).
26. Pharmacogenomics Research Network. www.pgrn.org/ (accessed 2016 Mar 16).
27. Relling MV, McDonagh EM, Chang T et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014; 96:169-74.
28. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90:625-9.
29. Relling MV, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011; 89:387-91.
30. Scott SA, Sangkuhl K, Gardner EE et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011; 90:328-32.
31. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450-2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012; 91:321-6.
32. Martin MA, Klein TE, Dong BJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012; 91:734-8.
33. Wilke RA, Ramsey LB, Johnson SG et al. Clinical Pharmacogenetics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012; 92:112-7.
34. Caudle KE, Thorn C F, Klein TE et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013; 94:640-5.
35. Hershfield MS, Callaghan JT, Tassaneeyakul W et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013; 93:153-8.
36. Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013; 93:402-8.
37. Leckband SG, Kelsoe JR, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013; 94:324-8.
38. Relling MV, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013; 93:324-5.
39. Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94:317-23.
40. Ramsey LB, Johnson SG, Caudle KE et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014; 96:423-8.
41. Clancy J P, Johnson SG, Yee SW et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther. 2014; 95:592-7.
42. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014; 95:376-82.
43. Martin MA, Hoffman JM, Freimuth RR et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014; 95:499-500.
44. Muir AJ, Gong L, Johnson SG et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-a-based regimens. Clin Pharmacol Ther. 2014; 95:141-6.
45. Gammal RS, Court MH, Haidar CE et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016; 99:363-9.
46. Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015; 98:127-34.
47. Birdwell KA, Decker B, Barbarino JM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015; 98:19-24.
48. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44-122.
49. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64:e139-228.
50. American Society of Health-System Pharmacists. Endorsed documents. www.ashp.org/menu/PracticePolicy/PolicyPositionsGuidelinesBestPrac-tices/BrowsebyDocumentType/EndorsedDocuments.aspx (accessed 2016 Mar 16).
51. Clinical Genome Resource. www.clinicalgenome.org/ (accessed 2016 Mar 16).
52. ClinVar. www.ncbi.nlm.nih.gov/clinvar/ (accessed 2016 Mar 16).
53. Clancy J P, Johnson SG, Yee SW et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther. 2014; 95:592-7.